Prospective observational study of taste assay in patients with solid tumors treated with standard chemotherapy (POTATO)

被引:1
|
作者
Giampieri, Riccardo [1 ,2 ]
Pelati, Elisa [3 ]
Mobili, Aurora Anna [3 ]
Copparoni, Cecilia [1 ]
Crocetti, Sonia [1 ]
Baleani, Maria Giuditta [1 ]
Pistelli, Mirco [1 ]
Pugnaloni, Sofia [3 ]
Alia, Sonila [3 ]
Mariani, Carlotta [3 ]
Vignini, Arianna [3 ]
Taus, Marina [3 ]
Berardi, Rossana [1 ,2 ]
机构
[1] Univ Politecn Marche, AOU Osped Riuniti Ancona, Oncol Clin, Ancona, Italy
[2] Univ Politecn Marche, Dipartimento Sci Clin & Mol, Ancona, Italy
[3] Univ Politecn Marche, AOU Osped Riuniti Ancona, Dietet & Nutr Clin, Ancona, Italy
关键词
Chemotherapy; Toxicity; Taste; Nausea; AMINO-ACIDS; EXPRESSION; GUSTDUCIN;
D O I
10.1007/s00520-020-05553-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The aim of our study is to evaluate taste changes in patients affected by solid tumors not involving oral cavity within the first month of standard chemotherapy. Methods In this monocentric, prospective, cohort study, we enrolled patients treated at our institution for different types of solid tumors between February and July 2019. Taste cotton swabs assay was used to assess taste changes. Results Thirty-one patients were enrolled and most of them had at least one change in taste. The taste that changed less was acid (42% of the population) whereas the one that changed the most was the perception of sweet (reduced in 35% of the population and increased in 45% of the population) and sour (reduced in 35% of the population). We did not find any statistical significant difference in terms of changes of taste and type of chemotherapy (emetogenic vs not, p > 0.05 for salty, sweet, bitter, and acid tastes). The type of primary tumor (breast vs GI-related) had a significant impact on perception of both salty (p = 0.0163) and acid (p = 0.0312) flavor. Furthermore, body mass composition assessed by BIA showed that obese patients had different changes in acid flavor vs non-obese patients (p = 0.04). This could not be proven when the assessment was made using BMI calculation. Conclusions Our study suggests that type of primary tumor (GI vs breast) more than type of chemotherapy used could be relevant in determining changes in taste during chemotherapy. Individualized dietary strategies based on these reported data are suggested, as to optimize patients' management.
引用
收藏
页码:851 / 858
页数:8
相关论文
共 50 条
  • [1] Prospective observational study of taste assay in patients with solid tumors treated with standard chemotherapy (POTATO)
    Riccardo Giampieri
    Elisa Pelati
    Aurora Anna Mobili
    Cecilia Copparoni
    Sonia Crocetti
    Maria Giuditta Baleani
    Mirco Pistelli
    Sofia Pugnaloni
    Sonila Alia
    Carlotta Mariani
    Arianna Vignini
    Marina Taus
    Rossana Berardi
    Supportive Care in Cancer, 2021, 29 : 851 - 858
  • [2] Oral Problems in Oncology Patients Undergoing Chemotherapy for Solid Tumors: A Prospective Observational Study
    Ottaviani, Giulia
    Targato, Giada
    Rupel, Katia
    Gobbo, Margherita
    Generali, Daniele
    Guglielmi, Alessandra
    Dicorato, Angela
    Adamo, Daniela
    Canfora, Federica
    Di Lenarda, Roberto
    Biasotto, Matteo
    CANCERS, 2024, 16 (01)
  • [3] Inpatient chemotherapy for patients with advanced solid tumors: A single-center observational study
    Soumerai, Tara
    Lei, Matthew
    Mulvey, Therese Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [4] G-CSF AS SECONDARY PROPHYLAXIS OF CHEMOTHERAPY-INDUCED NEUTROPENIA IN PATIENTS WITH SOLID TUMORS: RESULTS OF A PROSPECTIVE, OBSERVATIONAL STUDY
    Freyer, G.
    Jovenin, N.
    Yazbek, G.
    Villanueva, C. B.
    Hussain, A.
    Bethune, A.
    Rotarski, M.
    Simon, H.
    Boulanger, V.
    Hummerlsberger, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 499 - 500
  • [5] Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors
    Kyaw Z. Thein
    Sarina A. Piha-Paul
    Apostolia Tsimberidou
    Daniel D. Karp
    Filip Janku
    Siqing Fu
    Vivek Subbiah
    David S. Hong
    Timothy A. Yap
    Jatin Shah
    Denái R. Milton
    Lacey McQuinn
    Jing Gong
    Yanyan Tran
    Brett W. Carter
    Rivka Colen
    Funda Meric-Bernstam
    Aung Naing
    Experimental Hematology & Oncology, 10
  • [6] Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors
    Thein, Kyaw Z.
    Piha-Paul, Sarina A.
    Tsimberidou, Apostolia
    Karp, Daniel D.
    Janku, Filip
    Fu, Siqing
    Subbiah, Vivek
    Hong, David S.
    Yap, Timothy A.
    Shah, Jatin
    Milton, Denai R.
    McQuinn, Lacey
    Gong, Jing
    Tran, Yanyan
    Carter, Brett W.
    Colen, Rivka
    Meric-Bernstam, Funda
    Naing, Aung
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2021, 10 (01)
  • [7] Pain in neurosurgically treated patients: a prospective observational study
    Klimek, M
    Ubben, JFH
    Ammann, J
    Borner, U
    Klein, J
    Verbrugge, SJC
    JOURNAL OF NEUROSURGERY, 2006, 104 (03) : 350 - 359
  • [8] A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice
    Barni, S.
    Lorusso, V.
    Giordano, M.
    Sogno, G.
    Gamucci, T.
    Santoro, A.
    Passalacqua, R.
    Iaffaioli, V.
    Zilembo, N.
    Mencoboni, M.
    Roselli, M.
    Pappagallo, G.
    Pronzato, P.
    MEDICAL ONCOLOGY, 2014, 31 (01)
  • [9] Comprehensive geriatric assessment, patterns of care, and outcome of palliative chemotherapy in elderly patients with advanced solid tumors: A prospective observational study from India
    Khanna, M.
    Sundriyal, D.
    Kapoor, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S1575 - S1575
  • [10] A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice
    S. Barni
    V. Lorusso
    M. Giordano
    G. Sogno
    T. Gamucci
    A. Santoro
    R. Passalacqua
    V. Iaffaioli
    N. Zilembo
    M. Mencoboni
    M. Roselli
    G. Pappagallo
    P. Pronzato
    Medical Oncology, 2014, 31